$PSIG

PS International Has 180 Days to Meet Nasdaq’s $35M Threshold

PS International Group Ltd. (Nasdaq: PSIG) said Nasdaq issued a non-compliance notice dated Aug. 12, 2026 for failing the Nasdaq Capital Market minimum Market Value of Listed Securities requirement of $35 million. The company also does not meet alternatives for $2.5 million equity or $500,000 annual net income. Nasdaq granted 180 days, until Feb. 8, 2027, to regain compliance; shares continue trading.

Original reporting
Published Aug 14, 2026, 8:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 15, 2026, 6:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefRegulation
Primary signal
$PSIG
Bearish
medium confidence
Mentioned
$PSIG
Relevance
7/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$PSIGBearishMed
01

Why it matters

The deficiency letter creates a time-bound compliance objective and increases perceived delisting risk, which can affect liquidity, cost of capital, and investor positioning until compliance is demonstrated.

02

Market read

A defined Nasdaq compliance deadline (Feb 8, 2027) and specific MVLS cure condition can drive trading around market-cap recovery signals.

03

What to watch

The cure requires MVLS to close at or above $35M for at least 10 consecutive trading days, so traders should watch for any capital-market actions that can lift market cap rather than focusing only on the deficiency letter.

Relevance 7/10Novelty 7/10Timing: after-hours disclosure dated Aug 14, 2026, with 180-day cure clock starting Aug 12 notice

Background

Nasdaq Capital Market issuers must maintain minimum Market Value of Listed Securities (MVLS) and can also qualify via alternative equity or net income thresholds.

Company-level read

Ticker impact

$PSIGBearishMedium confidence
Context

PS International Group received a Nasdaq non-compliance notice for failing the $35M MVLS requirement and was granted 180 days to cure.

Expected impact

Near-term downside bias and higher volatility until MVLS compliance is evidenced; relief possible if MVLS closes above $35M for 10 consecutive sessions before the deadline.

Evidence & confidence

The article discloses a specific Nasdaq deficiency, the applicable rule set, and a defined cure window ending Feb 8, 2027, which directly affects listing risk premium.

Market effects

Highlights ongoing listing-compliance pressure for small-cap logistics and other low-MVLS issuers on Nasdaq Capital Market.

Limited direct regional spillover; primarily affects US-listed microcap sentiment.

Low global relevance; mostly a US exchange compliance event.

Counterpoint

The notice includes no immediate suspension or delisting, so the market may over-discount the risk if management can quickly boost market value via financing or corporate actions.

Key entities

  • PS International Group Ltd.

    Nasdaq-listed logistics and supply chain provider that received the MVLS non-compliance notice.

  • Nasdaq Stock Market LLC

    Exchange that issued the listing qualifications deficiency letter under Rule 5550(b)(2) and related rules.

Related articles

$PSIGMed

PS International Group Ltd. Receives Nasdaq Deficiency Notice for Minimum Market Value of Listed Securities Requirement

PS International Group Ltd. (Nasdaq: PSIG) said Nasdaq issued an Aug. 12, 2026 deficiency notice for failing the Nasdaq Capital Market minimum Market Value of Listed Securities requirement of $35 million. Nasdaq found PSIG also did not meet equity ($2.5 million) or net income ($0.5 million) alternatives. PSIG has until Feb. 8, 2027 to cure; no immediate delisting.

$LLYMed

New once-daily weight loss pill now available in pharmacies across UK

Eli Lilly's new weight loss and diabetes pill, orforglipron (Foundayo), is now available in UK pharmacies. It's the second GLP-1 pill for weight loss in the UK, after Wegovy. The MHRA authorized it earlier this month. Eli Lilly is working with the NHS on potential health service rollout. The pill is for patients with BMI 30+ or BMI 27-30 with weight-related conditions. Dosage starts at 0.8mg, increasing monthly. Pharmacists highlight its significance for patients avoiding injectables.